The potential in vitro activities aligns with high affinity for HER2 critical for breast and other cancers (Cheng, 2024; Rubin et al., 2024). Thus, in HER2-positive and triple-negative subtypes, HDM2 overexpression correlates with poor prognosis leading to breast cancer. But no correlation was found. Here, ERBB2 is linked to breast carcinoma.